Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Vaccines01:30

Cancer Vaccines

1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence and impact of pseudoprogression and mixed responses in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab: a retrospective analysis.

Acta oncologica (Stockholm, Sweden)·2026
Same author

Prognostic and Predictive Value of the Clearseq1-4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma.

Cancer research communications·2026
Same author

Distinct tumor immune microenvironmental landscapes drive divergent immunotherapy responses in glioblastoma.

Neuro-oncology·2026
Same author

Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity.

Molecular oncology·2026
Same author

Impact of time-of-day administration of immune checkpoint inhibitors on survival outcomes in patients with recurrent/metastatic head and neck cancer (R/M HNSCC): a retrospective cohort study.

Oral oncology·2025
Same author

The diversity of CD8<sup>+</sup> T cell dysfunction in cancer and viral infection.

Nature reviews. Immunology·2025
Same journal

Preclinical proof of concept for a personalized SNAPâ„¢-TIL (Specific Neo-Antigen Peptides-TIL) therapy platform.

Oncoimmunology·2026
Same journal

Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.

Oncoimmunology·2026
Same journal

The peripheral immune landscape of human breast cancer.

Oncoimmunology·2026
Same journal

Ex vivo-generated conventional dendritic cells type 1 and type 2 from blood progenitors induce potent antigen-specific T-cell immunity.

Oncoimmunology·2026
Same journal

Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.

Oncoimmunology·2026
Same journal

Early neutrophil infiltration promotes TRIMELVax-induced antitumor immunity by linking local inflammation to tumor control.

Oncoimmunology·2026
See all related articles

Related Experiment Video

Updated: Feb 24, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.3K

Trial watch: Dendritic cell-based anticancer immunotherapy.

Abhishek D Garg1, Monica Vara Perez1, Marco Schaaf1

  • 1Cell Death Research & Therapy (CDRT) Lab, Department of Cellular & Molecular Medicine, KU Leuven University of Leuven, Leuven, Belgium.

Oncoimmunology
|August 17, 2017
PubMed
Summary
This summary is machine-generated.

Dendritic cell (DC)-based cancer vaccines activate tumor-specific T cells. Emerging immunotherapies are reshaping the role of DC vaccines in cancer treatment.

Keywords:
Antigen cross-presentationDAMPsTLR signalingimmune-checkpoint blockersplasmacytoid dendritic cellstumor-infiltrating lymphocytes

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.1K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.8K

Related Experiment Videos

Last Updated: Feb 24, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.3K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.1K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.8K

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Dendritic cell (DC)-based vaccines are a key strategy in cancer immunotherapy.
  • These vaccines involve loading patient DCs with tumor-associated antigens (TAAs) and stimulating them with maturation cocktails.
  • DC vaccines have shown efficacy in activating tumor-specific T cells in preclinical and clinical studies.

Purpose of the Study:

  • To review current trends in DC-based cancer therapeutic development.
  • To examine how novel immunotherapies impact the clinical application of DC vaccines.
  • To highlight the evolving landscape of cancer immunotherapy.

Main Methods:

  • Survey of preclinical and clinical research on DC-based anticancer therapeutics.
  • Analysis of the integration of DC vaccines with other immunotherapies.
  • Review of recent advancements in immune checkpoint blockers and adoptive T-cell transfer.

Main Results:

  • DC vaccines effectively generate and enhance TAA-specific effector T cells.
  • DC vaccines facilitate T cell infiltration into the tumor microenvironment.
  • New immunotherapies are redefining the therapeutic niche for DC-based vaccines.

Conclusions:

  • DC-based vaccines remain a valuable tool in cancer immunotherapy.
  • The combination of DC vaccines with other immunotherapies holds significant promise.
  • The field of cancer immunotherapy is rapidly evolving, with DC vaccines playing a dynamic role.